Kairos Pharma to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial
Reuters
Sep 11, 2025
<a href="https://laohu8.com/S/KAPA">Kairos Pharma</a> to Host KOL Event Discussing Promising Interim Efficacy Results of ENV105 in Advanced Prostate Cancer Trial
Kairos Pharma Ltd. has announced a forthcoming virtual Key Opinion Leader $(KOL)$ event to discuss the interim efficacy results of its Phase 2 trial for ENV105, a first-in-class CD105 antagonist, in treating advanced prostate cancer. The event is scheduled for September 18th and will feature perspectives from principal investigators involved in the trial. The interim safety analysis reported in July indicated that ENV105 was well tolerated when combined with standard hormone therapy, apalutamide, in the initial 10 patients, with no dose-limiting toxicities or unexpected adverse events observed. Participants can register to receive access to the webcast, where experts including Dr. Neil Bhowmick, Dr. Umang Swami, Dr. Richard Lee, and Dr. Edwin Posadas will provide insights on the trial results and the potential role of ENV105 in addressing cancer drug resistance.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911712367) on September 11, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.